Sign Out
The highest dose of spesolimab administered in clinical trials was 1,200 mg. Adverse reactions observed in subjects receiving single or repeated doses up to 1,200 mg were consistent with the known safety profile of spesolimab.
In the event of overdose, it is recommended that the patient be monitored for any signs or symptoms of adverse reactions and symptomatic treatment be instituted as appropriate.
